151 related articles for article (PubMed ID: 18378521)
1. ACE inhibitors in cardiovascular disease--unbeatable?
McMurray JJ
N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
[No Abstract] [Full Text] [Related]
2. Telmisartan, ramipril, or both in patients at high risk of vascular events.
Büchner N; Banas B; Krämer BK
N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
[No Abstract] [Full Text] [Related]
3. [What is better here: ACE inhibitor or AT1 blocker?].
MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
[No Abstract] [Full Text] [Related]
4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
5. ONTARGET: questions asked, questions answered.
Weber MA
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
[No Abstract] [Full Text] [Related]
6. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
7. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
8. ONTARGET should not be over interpreted.
Abutaleb N
Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
[No Abstract] [Full Text] [Related]
9. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
[No Abstract] [Full Text] [Related]
10. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Düsing R; Nitschmann S
Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
[No Abstract] [Full Text] [Related]
11. Is therapy of people with chronic kidney disease ONTARGET?
Mann JF; Tobe S; Teo KK; Yusuf S
Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
[No Abstract] [Full Text] [Related]
12. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
13. Proteinuria: Is the ONTARGET renal substudy actually off target?
Ruggenenti P; Remuzzi G
Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
[No Abstract] [Full Text] [Related]
14. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
Burnier M; Waeber B; Hess O; Lüscher T
Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
[No Abstract] [Full Text] [Related]
15. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
16. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
[No Abstract] [Full Text] [Related]
17. Lessons learned from the ONTARGET and TRANSCEND trials.
Basile J
Curr Atheroscler Rep; 2009 Sep; 11(5):371-6. PubMed ID: 19664381
[TBL] [Abstract][Full Text] [Related]
18. [Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
Liakishev AA
Kardiologiia; 2008; 48(5):72. PubMed ID: 18537808
[No Abstract] [Full Text] [Related]
19. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]